

RECEIVED
CENTRAL FAX CENTER

NO. 308 P.4

MAR 22 2005

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Fax No. 1-703-872-9306 on

March 22, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: Anthony Ban

PATENT
Attorney Docket No.: 15270J-4727US
Client Ref. No.: 209-US-CIP4C2

*Fee Purposes
Only*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 10/816,022

Filed: March 31, 2004

Patent No.: 6,866,850

Issue Date: March 15, 2005

For: PREVENTION AND TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/816,022 Issued as U.S. Patent No. 6,866,850 (the "850 PATENT")
2. Application No. 09/723,762 Issued as U.S. Patent No. 6,787,144 (the "144 PATENT")

SCHENK, Dale B.
Application No.: 10/816,022
Page 3

PATENT

DECLARATION

The undersigned declares further that all statements made herein of her own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
JOL:RLC:aeb
80449829 v1

